Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid.

Maternal use of valproic acid (VPA) during pregnancy has been implicated in the aetiology of autism spectrum disorders in children, and rodents prenatally exposed to VPA showed behavioural alterations similar to those observed in humans with autism. However, the exact mechanism for VPA-induced behavioural alterations is not known. To study this point, we examined the effects of prenatal exposure to VPA and valpromide, a VPA analog lacking histone deacetylase inhibition activity, on behaviours, cortical pathology and histone acetylation levels in mice. Mice exposed to VPA at embryonic day 12.5 (E12.5), but not at E9 and E14.5, displayed social interaction deficits, anxiety-like behaviour and memory deficits at age 4-8 wk. In contrast to male mice, the social interaction deficits (a decrease in sniffing behaviour) were not observed in female mice at age 8 wk. The exposure to VPA at E12.5 decreased the number of Nissl-positive cells in the middle and lower layers of the prefrontal cortex and in the lower layers of the somatosensory cortex at age 8 wk. Furthermore, VPA exposure caused a transient increase in acetylated histone levels in the embryonic brain, followed by an increase in apoptotic cell death in the neocortex and a decrease in cell proliferation in the ganglionic eminence. In contrast, prenatal exposure to valpromide at E12.5 did not affect the behavioural, biochemical and histological parameters. Furthermore, these findings suggest that VPA-induced histone hyperacetylation plays a key role in cortical pathology and abnormal autism-like behaviours in mice.

[1]  D. O’Carroll,et al.  Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression , 2002, The EMBO journal.

[2]  R. Adolphs The neurobiology of social cognition , 2001, Current Opinion in Neurobiology.

[3]  P. Arlotta,et al.  Neuronal subtype specification in the cerebral cortex , 2007, Nature Reviews Neuroscience.

[4]  M. Rutter,et al.  Autism , 1978, Springer US.

[5]  D. Molfese,et al.  Regulation of Histone Acetylation during Memory Formation in the Hippocampus* , 2004, Journal of Biological Chemistry.

[6]  R. Przewłocki,et al.  Environmental Enrichment Reverses Behavioral Alterations in Rats Prenatally Exposed to Valproic Acid: Issues for a Therapeutic Approach in Autism , 2006, Neuropsychopharmacology.

[7]  E. Arenas,et al.  Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway , 2008, BMC Cell Biology.

[8]  B. Scatton,et al.  Inhibitory influence of GABA on central serotonergic transmission. Involvement of the habenulo-raphe´pathways in the GABAergic inhibition of ascending cerebral serotonergic neurons , 1985, Brain Research.

[9]  T. Eckschlager,et al.  Valproic acid in the complex therapy of malignant tumors. , 2010, Current drug targets.

[10]  C. McDougle,et al.  Structural and functional magnetic resonance imaging of autism spectrum disorders , 2011, Brain Research.

[11]  W. Freed,et al.  Cocaine causes deficits in radial migration and alters the distribution of glutamate and GABA neurons in the developing rat cerebral cortex , 2011, Synapse.

[12]  Jindrich Cinatl,et al.  Anti‐tumor mechanisms of valproate: A novel role for an old drug , 2002, Medicinal research reviews.

[13]  C. Lord,et al.  Behavioural phenotyping assays for mouse models of autism , 2010, Nature Reviews Neuroscience.

[14]  Eric Courchesne,et al.  Brainstem, cerebellar and limbic neuroanatomical abnormalities in autism , 1997, Current Opinion in Neurobiology.

[15]  M. Carducci,et al.  Multiple Molecular pathways explain the anti‐proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo , 2007, The Prostate.

[16]  D. Gilliam,et al.  Genetic and maternal effects on valproic acid teratogenesis in C57BL/6J and DBA/2J mice. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  Armin Schumacher,et al.  The Nuclear Kinase Mitogen- and Stress-Activated Protein Kinase 1 Regulates Hippocampal Chromatin Remodeling in Memory Formation , 2007, The Journal of Neuroscience.

[18]  D. Geschwind,et al.  Autism spectrum disorders: developmental disconnection syndromes , 2007, Current Opinion in Neurobiology.

[19]  H. Damasio,et al.  Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. , 2000, Brain : a journal of neurology.

[20]  J. Hersh,et al.  A male with fetal valproate syndrome and autism , 1997, Developmental medicine and child neurology.

[21]  B. Kerr,et al.  Fetal valproate syndrome and autism , 2001 .

[22]  Christoph Schmitz,et al.  Neurons in the fusiform gyrus are fewer and smaller in autism. , 2008, Brain : a journal of neurology.

[23]  P. Turnpenny,et al.  A clinical study of 57 children with fetal anticonvulsant syndromes , 2000 .

[24]  G. Bartzokis,et al.  Biological underpinnings of treatment resistance in schizophrenia: an hypothesis. , 2003, Psychopharmacology bulletin.

[25]  M. Eadie Antiepileptic drugs as human teratogens , 2008 .

[26]  S. Purgato,et al.  p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. , 2005, Oncology reports.

[27]  H. Nau,et al.  S-2-PENTYL-4-PENTYNOIC HYDROXAMIC ACID AND ITS METABOLITE S-2-PENTYL-4-PENTYNOIC ACID IN THE NMRI-EXENCEPHALY-MOUSE MODEL: PHARMACOKINETIC PROFILES, TERATOGENIC EFFECTS, AND HISTONE DEACETYLASE INHIBITION ABILITIES OF FURTHER VALPROIC ACID HYDROXAMATES AND AMIDES , 2006, Drug Metabolism and Disposition.

[28]  S. Moy,et al.  Mouse models of autism spectrum disorders: The challenge for behavioral genetics , 2006, American journal of medical genetics. Part C, Seminars in medical genetics.

[29]  L. Wing,et al.  Early childhood autism : clinical, educational and social aspects , 1966 .

[30]  M. Guenther,et al.  Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen* , 2001, The Journal of Biological Chemistry.

[31]  K. Reuhl,et al.  A New Neurobehavioral Model of Autism in Mice: Pre- and Postnatal Exposure to Sodium Valproate , 2006, Journal of autism and developmental disorders.

[32]  S. Aizawa,et al.  Absence of Cajal-Retzius cells and subplate neurons associated with defects of tangential cell migration from ganglionic eminence in Emx1/2 double mutant cerebral cortex. , 2002, Development.

[33]  T. Henry The history of valproate in clinical neuroscience. , 2003, Psychopharmacology bulletin.

[34]  M. Coleman A Report on the Autistic Syndromes , 1978 .

[35]  L. Thompson,et al.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders , 2008, Nature Reviews Drug Discovery.

[36]  D. deCatanzaro,et al.  Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid , 2010, Neuroscience.

[37]  H. Mizoguchi,et al.  17β-estradiol attenuates hippocampal neuronal loss and cognitive dysfunction induced by chronic restraint stress in ovariectomized rats , 2007, Neuroscience.

[38]  J. Greenwood,et al.  Valproic acid induces caspase 3-mediated apoptosis in microglial cells , 2006, Neuroscience.

[39]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[40]  P. Rodier,et al.  Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. , 2000, Neurotoxicology and teratology.

[41]  Wolfgang Schmid,et al.  Disruption of CREB function in brain leads to neurodegeneration , 2002, Nature Genetics.

[42]  Angelica Ronald,et al.  Autism spectrum disorders and autistic traits: A decade of new twin studies , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[43]  L. Winn,et al.  Epigenetic modifications in valproic acid-induced teratogenesis. , 2010, Toxicology and applied pharmacology.

[44]  O. Marín,et al.  A long, remarkable journey: Tangential migration in the telencephalon , 2001, Nature Reviews Neuroscience.

[45]  J. Gustafsson,et al.  Estrogen receptor (ER)β knockout mice reveal a role for ERβ in migration of cortical neurons in the developing brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  C. Salafia,et al.  Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gamma. , 2006, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[47]  H. Markram,et al.  Abnormal Fear Conditioning and Amygdala Processing in an Animal Model of Autism , 2008, Neuropsychopharmacology.

[48]  K. Mikoshiba,et al.  Neuronal Birthdate-Specific Gene Transfer with Adenoviral Vectors , 2004, The Journal of Neuroscience.

[49]  Kwang Ho Ko,et al.  The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. , 2011, Toxicology letters.

[50]  T. Bourgeron,et al.  Searching for ways out of the autism maze: genetic, epigenetic and environmental clues , 2006, Trends in Neurosciences.

[51]  A. Ornoy Valproic acid in pregnancy: how much are we endangering the embryo and fetus? , 2009, Reproductive toxicology.

[52]  H. Manji,et al.  Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers , 2004, Molecular Psychiatry.

[53]  M. Beale,et al.  Psychotropic drug-induced weight gain alleviated with orlistat: a case series. , 2003, Psychopharmacology bulletin.

[54]  P. Kwan,et al.  The mechanisms of action of commonly used antiepileptic drugs. , 2001, Pharmacology & therapeutics.

[55]  Ryszard Przewłocki,et al.  Behavioral Alterations in Rats Prenatally Exposed to Valproic Acid: Animal Model of Autism , 2005, Neuropsychopharmacology.